Adaptimmune initiates Multiple Myeloma drug Phase I/II clinical trial
The dual site, two-cohort, open-label clinical trial is intended to assess the safety, bioactivity and anti tumor effect of infusion of patients’ own T cells that have been
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.